Clinical and Biochemical Characteristics of Acromegalic Patients Stratified According to the Presence of AHR and/or AIP Variants (VAR+) or not (VAR−), and to the Area Where They Had Lived Before Diagnosis
| Characteristic . | HR/VAR+ . | HR/VAR− . | P . | NP/VAR+ . | NP/VAR− . | P . |
|---|---|---|---|---|---|---|
| Cases, n | 9 | 14 | NS | 44 | 143 | NS |
| Male sex, n | 5 | 7 | NS | 17 | 50 | NS |
| Age at diagnosis, y | 41.0 ± 6.2 | 47.5 ± 3.6 | NS | 48.9 ± 2.5 | 46.6 ± 1.1 | NS |
| Mean GH levels at diagnosis, μg/L | 8.0 ± 3.4 | 15.4 ± 5.5 | NS | 16.4 ± 3.3 | 14.7 ± 1.8 | NS |
| Mean IGF-I levels at diagnosis, ×ULN | 4.3 ± 0.1 | 2.5 ± 0.2 | <.001 | 2.8 ± 0.2 | 2.8 ± 0.1 | NS |
| Mean pituitary tumor diameter, mm | 24.2 ± 3.7 | 12.1 ± 3.3 | <.02 | 16.4 ± 2.5 | 15.9 ± 1.3 | NS |
| Macroadenomas, n | 6 | 9 | NS | 31 | 98 | NS |
| FIPA | 0 | 1 | NS | 1 | 3 | NS |
| Characteristic . | HR/VAR+ . | HR/VAR− . | P . | NP/VAR+ . | NP/VAR− . | P . |
|---|---|---|---|---|---|---|
| Cases, n | 9 | 14 | NS | 44 | 143 | NS |
| Male sex, n | 5 | 7 | NS | 17 | 50 | NS |
| Age at diagnosis, y | 41.0 ± 6.2 | 47.5 ± 3.6 | NS | 48.9 ± 2.5 | 46.6 ± 1.1 | NS |
| Mean GH levels at diagnosis, μg/L | 8.0 ± 3.4 | 15.4 ± 5.5 | NS | 16.4 ± 3.3 | 14.7 ± 1.8 | NS |
| Mean IGF-I levels at diagnosis, ×ULN | 4.3 ± 0.1 | 2.5 ± 0.2 | <.001 | 2.8 ± 0.2 | 2.8 ± 0.1 | NS |
| Mean pituitary tumor diameter, mm | 24.2 ± 3.7 | 12.1 ± 3.3 | <.02 | 16.4 ± 2.5 | 15.9 ± 1.3 | NS |
| Macroadenomas, n | 6 | 9 | NS | 31 | 98 | NS |
| FIPA | 0 | 1 | NS | 1 | 3 | NS |
Clinical and Biochemical Characteristics of Acromegalic Patients Stratified According to the Presence of AHR and/or AIP Variants (VAR+) or not (VAR−), and to the Area Where They Had Lived Before Diagnosis
| Characteristic . | HR/VAR+ . | HR/VAR− . | P . | NP/VAR+ . | NP/VAR− . | P . |
|---|---|---|---|---|---|---|
| Cases, n | 9 | 14 | NS | 44 | 143 | NS |
| Male sex, n | 5 | 7 | NS | 17 | 50 | NS |
| Age at diagnosis, y | 41.0 ± 6.2 | 47.5 ± 3.6 | NS | 48.9 ± 2.5 | 46.6 ± 1.1 | NS |
| Mean GH levels at diagnosis, μg/L | 8.0 ± 3.4 | 15.4 ± 5.5 | NS | 16.4 ± 3.3 | 14.7 ± 1.8 | NS |
| Mean IGF-I levels at diagnosis, ×ULN | 4.3 ± 0.1 | 2.5 ± 0.2 | <.001 | 2.8 ± 0.2 | 2.8 ± 0.1 | NS |
| Mean pituitary tumor diameter, mm | 24.2 ± 3.7 | 12.1 ± 3.3 | <.02 | 16.4 ± 2.5 | 15.9 ± 1.3 | NS |
| Macroadenomas, n | 6 | 9 | NS | 31 | 98 | NS |
| FIPA | 0 | 1 | NS | 1 | 3 | NS |
| Characteristic . | HR/VAR+ . | HR/VAR− . | P . | NP/VAR+ . | NP/VAR− . | P . |
|---|---|---|---|---|---|---|
| Cases, n | 9 | 14 | NS | 44 | 143 | NS |
| Male sex, n | 5 | 7 | NS | 17 | 50 | NS |
| Age at diagnosis, y | 41.0 ± 6.2 | 47.5 ± 3.6 | NS | 48.9 ± 2.5 | 46.6 ± 1.1 | NS |
| Mean GH levels at diagnosis, μg/L | 8.0 ± 3.4 | 15.4 ± 5.5 | NS | 16.4 ± 3.3 | 14.7 ± 1.8 | NS |
| Mean IGF-I levels at diagnosis, ×ULN | 4.3 ± 0.1 | 2.5 ± 0.2 | <.001 | 2.8 ± 0.2 | 2.8 ± 0.1 | NS |
| Mean pituitary tumor diameter, mm | 24.2 ± 3.7 | 12.1 ± 3.3 | <.02 | 16.4 ± 2.5 | 15.9 ± 1.3 | NS |
| Macroadenomas, n | 6 | 9 | NS | 31 | 98 | NS |
| FIPA | 0 | 1 | NS | 1 | 3 | NS |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
